Rallybio

Rallybio Goodwill

Goodwill of Rallybio (RLYB) as of Oct 17, 2026.

Goodwill

-USD

Last updated:

Goodwill of Rallybio is 2026 - USD. Goodwill of Rallybio was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rallybio Stock analysis

What does Rallybio do? Rallybio Corp is a biotechnology company headquartered in New Haven, Connecticut. It focuses on the research, development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company employs 44 full-time employees. Rallybio Corp went public on July 29, 2021. Its pipeline includes RLYB212, RLYB116, RLYB114, RLYB331, and the ENPP1 Program. RLYB212 is a subcutaneously administered human monoclonal anti-HPA-1a antibody candidate for preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). RLYB116 is a complement component 5 inhibitor for treating conditions such as paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rallybio stock

On Eulerpool you can find the complete historical development of Goodwill Rallybio since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Rallybio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Rallybio

All Key Metrics — Rallybio